As systemic therapies with crizotinib could have a better control of extracranial disease, BM is a major barrier to the successful long‐term treatment of patients with ROS1+NSCLC, probably because of poor penetration of crizotinib into the central nervous system. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.